PMV Pharmaceuticals (PMVP) AI Stock Analysis

• Market Cap: $63.36M
• Dividend Yield: N/A
• Average Volume (3M): 123.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.24
• Revenue Growth: N/A
• EPS Growth: 21.33%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -1.14
• Shares Outstanding: 51,933,605
• 10 Day Avg. Volume: 147,765
• 30 Day Avg. Volume: 123,417
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 391.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

PMV Pharmaceuticals scores low primarily due to its pre-revenue status, characterized by high R&D expenses leading to significant losses and negative cash flows. The strong cash position offers some cushion, but the absence of revenue and declining equity raise concerns about sustainability. Technical indicators suggest bearish momentum, while valuation metrics reflect the lack of profitability, limiting immediate investment appeal.

Positive Factors

Clinical Trial Progress

Enrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.

New Collaborations

PMV is collaborating with MD Anderson and MSK on a new study evaluating rezatapopt in combination with azacitidine for specific cancers, with enrollment beginning soon.

Negative Factors

Clinical Trial Setbacks

The Keytruda combo arm of PYNNACLE was discontinued due to limited clinical benefit.

PMV Pharmaceuticals Business Overview & Revenue Model

Company Description

PMV Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which are the most common mutations found in human cancers. The company operates within the healthcare and biotechnology sectors, aiming to provide transformative treatments that specifically target cancer's genetic drivers.

How the Company Makes Money

PMV Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company focuses on advancing its pipeline of small-molecule therapies through clinical trials and aims to monetize these assets via out-licensing agreements, partnerships with larger pharmaceutical companies, or direct sales upon regulatory approval. Key revenue streams include milestone payments, royalties, and upfront fees from partnerships and collaborations, which are essential to funding ongoing research and development efforts. The company's financial success is closely tied to the successful advancement of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

PMV Pharmaceuticals Financial Statement Overview

Summary

PMV Pharmaceuticals is in a typical pre-revenue phase for a biotech firm, focusing heavily on R&D. Despite strong cash reserves, the company faces high operational losses and negative cash flows, with no revenue generation. The low debt levels are a positive, but the decline in equity and assets is concerning for long-term sustainability.

Income Statement

PMV Pharmaceuticals has consistently reported zero revenue over the years, highlighting the typical operational phase of a biotech firm focused on R&D before product commercialization. The net income is negative, with increasing losses, indicating high operational expenses relative to non-existent revenues. The absence of revenue growth and weak profit margins reflect challenges in moving towards profitability.

Balance Sheet

The company's balance sheet shows a strong equity position with significant cash reserves, providing a buffer against the continued losses. The debt-to-equity ratio is low due to minimal debt levels, which is a positive sign. However, the continuous decline in stockholders' equity and asset base over the years is a concern, indicating potential long-term sustainability issues if the trend continues without revenue generation.

Cash Flow

PMV Pharmaceuticals exhibits negative operating and free cash flows, consistent with its stage in the biotech lifecycle. While free cash flow has improved slightly, it remains negative, reflecting high operational cash usage. The lack of positive cash flow from operations indicates reliance on external financing to sustain operations, posing a risk if capital markets become less favorable.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-1.26M	-650.00K	-1.28M	-318.00K
	EBIT
-85.45M	-80.13M	-77.04M	-58.29M	-34.94M
	EBITDA
-85.45M	-78.88M	-76.72M	-57.99M	-34.62M
	Net Income Common Stockholders
-58.71M	-68.96M	-73.32M	-57.85M	-34.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
169.45M	203.06M	241.05M	297.16M	361.42M
	Total Assets
191.29M	252.15M	270.31M	331.57M	365.53M
	Total Debt
1.19M	13.29M	13.98M	11.19M	0.00
	Net Debt
-39.69M	-24.42M	-94.32M	-161.27M	-361.42M
	Total Liabilities
15.21M	26.46M	24.28M	23.01M	6.41M
	Stockholders Equity
176.08M	225.69M	246.03M	308.56M	359.12M
Cash Flow		Free Cash Flow
-51.94M	-56.62M	-71.74M	-47.92M	-32.89M
	Operating Cash Flow
-51.28M	-55.66M	-63.76M	-46.57M	-32.74M
	Investing Cash Flow
53.35M	-50.55M	-1.37M	-143.58M	27.91M
	Financing Cash Flow
313.00K	35.58M	958.00K	2.02M	292.97M

PMV Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Negative. The current price of 1.22 is below the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.41, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 37.29 is Neutral, neither overbought nor oversold. The STOCH value of 14.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMVP.

PMV Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	77 Outperform	$5.29B	61.50	10.34%	―	473.02%	1620.44%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
DTIL	48 Neutral	$39.54M	98.04	24.44%	―	43.62%	―
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%
KPTI	41 Neutral	$62.62M	―	41.08%	―	-0.55%	49.85%
PMVP	39 Underperform	$63.36M	―	-29.23%	―	―	21.33%